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Current Perspectives of Transplantation Immunology Via The Intestine 
T.E. Starzl 
~ RECORDED history of intestinal transplantation 
.1 is a long one, stretching back to the beginning of this 
century and Alexis Carrel. However, the line of continuity 
contained long blankS, even after Richard Ullehei's presen-
tation of experimental~K~el replacement in dogs at the 
A:iilerican~puigical ASSoCiation in 1959,1 and his unsuccess-
fulfilst clinical trials 7 yean-later. Here, I will focus on the 
shifting perceptioIis of the immunologic barrier to this 
operation since the symposium held in London, England, in 
September 1988. 
By this time, the first two successful examples. of trans-
plantation of a functional human bowel had already been 
recorded but not yet published. The complete small intes-
tine and half of the colon were parts of a multivisceral graft 
transplanted in Pittsburgh in November 1987 to a child who 
lived more than 6 months before dying of a B-celllympho-
ma.2 A small intestinal segment was transferred from a 
living donor in the case of Deitz et al of Kiel during August 
19883; the patient ate during most of the 56 months survival. 
Now the pace quickened. During the 15 months following 
the London conference, Grant et al from London, Ontari04 
and Margreiter et al of Innsbruck5 added more long-
surviving intestine-containing grafts, and Goulet et al6 
performed an isolated complete cadaveric intestinal trans-
plantation in a child. Goulet et ai's patient is the only one 
still alive, but the two Canadian recipients survived for 5 
years. 
At the 1988 meeting in London. the general perception of 
intestinal transplantation was still defined by the classical 
rat study of Monchik and Russell.7 using a parent-to-
offspring F 1 hybrid model in which the recipient could not 
reject the graft. but was vulnerable to graft-versus-host 
disease (GVHD). When the recipients died of GVHD, the 
unchallenged impression for many subsequent years was 
that GVHD was going to be a critical management problem 
in clinical cases. Lurking also in the background was 
concern about transplanting a sac of gastrointestinal con-
tents. If the sac became permeable to bacteria, uncontrolled 
sepsis was expected to follow. The widespread pessimism 
about clinical application of intestinal transplantation was 
understandable. 
One of the main themes of the 1988 London meeting was 
how to eliminate the lymphoid tissue in the grafts by 
irradiation. antilymphocyte globulin (ALG). or even surgi-
cal lymphadenectomy. However. there also was a breeze 
blowing in a different direction. Arnaud-Battandier et alH 
from France (working with Goulet and Ricour). had shown 
in pigs as early as 1985 that the donor leukocytes in bowel 
began migrating to the spleen and elsewhere within a few 
minutes after revascularization. The departed 'ceUs were 
replaced in the intestine by leukocytes of' tgi~- :;~ientI 
~mingly without injury to··the ·sraftK··fncori~~ltiie 
French team had not cited these results in their~uent 
Publications and did not mention them in LOndOO; 'SOme of 
the histopathologic rat studies presented at thal' ineeilng by 
Oark and co-workers were consistent with the earlier 
French results. However, the important conclusion that the 
intestinal allograft had a dual cell construction was neither 
the point nor the interpretation of the English workers.9,10 
Meanwhile, armed with the new drug FK 506 (now 
tacrolimus), Murase et al11 reported at the 1989 European 
Society of Organ Transplantation (ESOT) meeting in Bar-
celona that rat bowel alone, or as part of a multivisceral 
complex, could be transplanted with routine success. A 
second article,12 describing the pathology of these grafts, 
was controversial, requiring extensive editorial negotiations 
that held up publication for more than a year. The most 
important pathologic observation (by Anthony J. [Jake] 
Demetris) was that the grafts had become genetic compos-
ites within 14 days. The leukocytes of the lamina propria 
and elsewhere, including in the donor mesenteric lympho-
cytes, were those of the recipient. This conclusion was made 
possible by the development in Pittsburgh of an antibody 
(L-21-6) that failed to stain the class II cells of Brown 
Norway recipients because of a defect in their invariant 
chain. but did so in essentially all other strains. 
Meanwhile. Satoru Todo and Andreas Tzakis had begun 
in early 1990 their now large clinical series of a whole range 
of inter-related visceral grafts and intestine alone using FK 
506 (tacrolimus)-based immunosuppression. IJ These pro-
cedures were construed to be variations of a multivisceral 
transplant operation described in 1960 in dOgsl4; used 
clinically by US,2 in Innsbruck.s and in Canada4; and ex-
ploited by Murase et al in rat studies. I 1.12 The organs were 
envisioned as grapes on an anatomic stem (Fig 1 )-to be 
left intact. picked off and discarded. or transplanted sepa-
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Fig 1. The complex of intraabdominal viscera (center) from 
which come liver-pancreas, intestine, pancreas, or liver grafts 
(periphery). 
rately.lS When the intestine was included in the allograft, it 
always was the Achilles' heel of the operation. 
In the human recipients, the bowel allografts showed the 
same transformation16 as had been observed by Arnaud-
Battandier et al8 and in rats. 12 It had been known for nearly 
20 years that this leukocyte replacement was characteristic 
2431 
of human hepatic allografts. 17 but it was assumed to be a 
special quality of liver transplants. Now it was realized that 
leukocyte replacement must be a generic phenomenon with 
the acceptance of all kinds of whole organ allografts. 16 
Although the fate of the departed donor cells was not 
known and would not be for another year, we understood 
the folly of deliberate donor leukocyte depletionl5 and 
realized that doing so generated the B-celllymphomas that 
crippled the clinical trials between 1987 and 1989.2•4.18 The 
management philosophies that had dominated the 1988 
transplant meeting took a sharp tum away from these 
practices by the time of the Second International Small 
Bowel Symposium hosted in October 1991 by David Grant, 
William Wall, and Calvin Stiller in London, Ontario. 
The observations of leukocyte migration and replace-
ment that were made in the course of research in intestinal 
transplantation eventually matured to the concept depicted 
in Figure 2 (lower panels). Before this time, transplantation 
had been defined largely in terms of a unidirectional 
immune reaction (Fig 2, upper panels): host versus defense-
less graft following organ transplantation (upper left) and 
graft versus defenseless host (GVH) after bone marrow 
transplantation (upper right). With either direction, this 
one-way paradigm had failed to elucidate numerous enig-
matic observations including the surprising clinical success 
of these procedures. However, it now appeared that the 
events following both varieties of transplantation might be 
explained by the previously unsuspected persistence of a 
trace population of immune cells. This was proved in organ 
transplant recipients in 1992 when donor leukocytes (mi-
crochimerism) were found in the skin, lymph nodes, blood, 
One-Way Paradigm (Organ) One-Way Paradigm (Bone Marrow) 
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Fig 2. The one- and two-way 
paradigms of immune interac-
tion following organ or bone 
marrow transplantation. 
2432 
and other locations in patients whose kidney or liver 
allografts had been functioning for up to 30 years.19-23 The 
implication was that donor stem cells present in the trans-
planted organ had migrated and survived in the recipi-
ent24-26 (Fig 2, lower left). 
In the mirror image condition that evolves after conven-
tional clinical bone marrow transplantation,19.26 the trace 
population consists of leukocytes of host origin (Fig 2, lower 
right), meaning that recipient stem cells survive and persist 
despite patient preconditioning with supralethal cytoabla-
tion.27•28 With either conventional organ or bone marrow 
transplantation, the quantitative disproportion of the coex-
isting donor and ,recipient leukocytes is, e~ormous •.. ~~r-: 
theless, there is. much circumstantial and direct. evidence 
that the tw~·~~iKCCip~ jii9<!ii!~~~jja1!t~D 
~nsiven~~gm!!:!g·~~mKK~~~O1g ... ogKI~~~ c!!~!l!~!£: 
tivity (the two-:~KmIUfDfldigmFK . "',,, •... ;o;..ri ,...,',,' .'" gIII~I;I ~ 
The implications of this concept at virtually every level of 
transplantation iinmunology have been discussed else-
where.19.20.26.29-32 The duality of the immune reaction 
following organ transplantation (HVG and GVH) is obvi-
ous after intestinal transplantation and was a dominant 
theme in the research and clinical presentations of this 
year's splendid program. It was appropriate that the pro-
gram was organized by Satom Todo, a genuine pioneer in 
the visceral transplantation field. 
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